Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 565 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cequa Clear all

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Indolent Non-Hodgkin Lymphoma, Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, Refractory Follicular Lymphoma, Refractory Hodgkin Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Non-Hodgkin Lymphoma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 69 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 6
States / cities: Aurora, Colorado • Denver, Colorado • Salt Lake City, Utah + 2 more

Conditions: Pharmacokinetics, Healthy
Interventions: Colchicine, Cyclosporine; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Osteogenesis Imperfecta
Interventions: Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide, Cyclosporin, Mesenchymal Stem Cell Transplantation, Busulfan; Other · Radiation · Drug + 1 more
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 3 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2007
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Large Granular Lymphocytic Leukemia, LGL Leukemia
Interventions: Cyclosporine, Gene expression analysis, Microarray analysis, Laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pemphigus
Interventions: Sirolimus (formerly known as Rapamycin); Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Irvine, California

Conditions: Immunosuppression, Renal Failure
Interventions: Arm A: Everolimus, Calcineurin Inhibitor; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Blood Cancer, Leukemia, Graft Versus Host Disease, Malignancy, CLL, NHL, Hodgkin's Disease, MDS
Interventions: non-myeloablative hematopoietic cell transplantation, Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil, G-CSF, Solumedrol, Acetaminophen, Diphenydramine, Hydrocortisone; Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 12 Months and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions: filgrastim, cyclophosphamide, cyclosporine, cytarabine, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Up to 55 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2005
U.S. locations: 13
States / cities: Stanford, California • Iowa City, Iowa • Lexington, Kentucky + 10 more

Conditions: Dermatitis, Atopic
Interventions: Not listed
Lead sponsor: Rady Children's Hospital, San Diego; Other
Eligibility: 2 Years to 17 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 3
States / cities: San Diego, California • San Francisco, California • Chicago, Illinois

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Cyclosporine, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 45 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cytomegalovirus Infections
Interventions: Letermovir; Drug
Lead sponsor: Amy C. Sherman, MD; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: End-Stage Renal Disease, Kidney Transplantation
Interventions: Cyclosporine, Sirolimus, Tacrolimus; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 20 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bronchiolitis Obliterans, Constructive Bronchiolitis, Graft Versus Host Disease, Bronchiolitis, Exudative, Bronchiolitis, Proliferative, Graft-Versus-Host Disease
Interventions: Cyclosporine Inhalation Solution (CIS); Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 10 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Diseases, Heart Transplantation
Interventions: Tacrolimus, Cyclosporine, Mycophenolate mofetil, Methylprednisolone, Prednisone; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: Not listed
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Graft Versus Host Disease
Interventions: cyclosporine, hydroxychloroquine, prednisone, tacrolimus; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 29 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 89
States / cities: Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more

Conditions: Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions: Nintedanib, Placebo, Standard of Care; Drug
Lead sponsor: Rohit Aggarwal, MD; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more

Conditions: Immunosuppression, Leukemia
Interventions: SOLEX 300i Stem Cell Selection; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 10 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Leukemia, Myelodysplasia
Interventions: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate; Procedure · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 1 Year to 65 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 28
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 22 more

Conditions: Failing Renal Allograft
Interventions: Belatacept, Calcineurin inhibitor therapy, Mycophenolate mofetil, prednisone; Drug
Lead sponsor: Andrew B Adams; Other
Eligibility: 18 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: End-stage Renal Disease, Renal Transplantation, Kidney Transplantation
Interventions: Conditioning Regimen; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dry Eye Disease
Interventions: CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops; Drug
Lead sponsor: Novaliq GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 27
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 23 more

Conditions: Leukemia
Interventions: therapeutic allogeneic lymphocytes, peripheral blood stem cell transplantation, radiation therapy; Biological · Procedure · Radiation
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 55 Years to 74 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 2
States / cities: Denver, Colorado • Seattle, Washington

Conditions: Kidney Transplantation
Interventions: Tacrolimus Modified Release (MR), Tacrolimus, cyclosporine microemulsion, mycophenolate mofetil; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 12 Years and older
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 48
States / cities: Birmingham, Alabama • Mobile, Alabama • Loma Linda, California + 36 more

Conditions: Acute Myeloid Leukemia
Interventions: peg-IFN-α, Hematopoietic Cell Transplant (HCT), Tacrolimus, Methotrexate; Drug · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Drug-Drug Interaction Study Between Colchicine and Cyclosporine

Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation

Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia

Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

Allogeneic Transplantation From Related Haploidentical Donors

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

Systemic Therapies for Pediatric Atopic Dermatitis

Aerosol Cyclosporine in Chronic Obstructive Pulmonary Disease (COPD)

Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans

Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

Myositis Interstitial Lung Disease Nintedanib Trial

Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignances

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Belatacept Therapy for the Failing Renal Allograft

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia

Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia